Segment information (Tables)

12 Months Ended

Dec. 31, 2019

Segment information for year 2019

(Euro, in thousands)


	R&D		Fee-for-services		Inter-segment elimination		Group
External revenue	€	834,901	€	10,084			€	844,985
Internal revenue				6,742	€	(6,742)
Other income		50,905		—				50,905
Revenues & other income		885,806		16,826		(6,742)		895,890

Segment result		407,464		1,125				408,589
Unallocated expenses (1)								(38,297)
Operating income								370,292
Financial (expenses)/income								(220,233)
Result before tax								150,060
Income taxes								(214)
Net income							€	149,845

(1)

The unallocated expenses of €38,297 thousand comprise warrant costs.

Segment information for year 2018

(Euro, in thousands)


	R&D		Fee-for-services		Inter-segment elimination		Group
External revenue	€	278,666	€	10,170			€	288,836
Internal revenue				8,508	€	(8,508)
Other income		29,000		9				29,009
Revenues & other income		307,666		18,687		(8,508)		317,845

Segment result		(19,734)		1,751				(17,983)
Unallocated expenses (1)								(26,824)
Operating loss								(44,807)
Financial (expenses)/income								15,598
Result before tax								(29,209)
Income taxes								(50)
Net loss							€	(29,259)

(1)

The unallocated expenses of €26,824 thousand principally comprise of €26,757 thousand of warrant costs.

Segment information for year 2017

(Euro, in thousands)


	R&D		Fee-for-services		Inter-segment elimination		Group
External revenue	€	118,262	€	8,825			€	127,087
Internal revenue				5,104	€	(5,104)
Other income		28,815		15				28,830
Revenues & other income		147,077		13,945		(5,104)		155,918

Segment result		(73,610)		86				(73,524)
Unallocated expenses (1)								(16,278)
Operating loss								(89,802)
Financial (expenses)/income								(25,705)
Result before tax								(115,507)
Income taxes								(198)
Net loss							€	(115,704)

(1)

The unallocated expenses of €16,278 thousand principally comprise of €16,536 thousand of warrant costs.

Summary of revenues by destination


	Year ended December 31,
	2019		2018		2017
	(Euro, in thousands)
North America	€	795,605	€	117,609	€	82,050
Europe		49,018		171,113		45,037
Asia Pacific		362		114		—
Total	€	844,985	€	288,836	€	127,087

Summary of revenues by major customers


	Year ended December 31,
	2019				2018				2017
Spilt up of revenues by major customers	(Euro, in thousands)		%		(Euro, in thousands)		%	(Euro, in thousands)		%
Gilead:
North America (1)	€	793,873	94%		€	116,640	40%	€	80,687	63%
Europe (1)		(4,570)	-1%			7,793	3%
AbbVie:
Europe		26,356	3%			89,936	31%		34,049	27%
Novartis:
Europe		19,177	2%			55,218	19%
Les Laboratoires Servier:
Europe		—	0%			9,000	3%		67	0%
Total revenues from major customers	€	834,836	99%	€		278,587	96%		114,804	90%

Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019, included a negative catch-up effect on closing date of €245.9 million resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.